Harmonizing antibiotic regimens with renal replacement therapy

被引:5
作者
Jang, Soo Min [1 ]
Lewis, Susan J. [2 ]
Mueller, Bruce A. [3 ]
机构
[1] Loma Linda Univ, Dept Pharm Practice, Sch Pharm, Loma Linda, CA 92350 USA
[2] Univ Findlay, Dept Pharm Practice, Coll Pharm, Findlay, OH USA
[3] Michigan Coll Pharm, Clin Pharm Dept, Ann Arbor, MI USA
关键词
Renal replacement therapy; acute kidney injury; antibiotics; pharmacokinetics; pharmacodynamics; CRITICALLY-ILL PATIENTS; CONTINUOUS VENOVENOUS HEMOFILTRATION; GENTAMICIN PHARMACOKINETICS; POPULATION PHARMACOKINETICS; VANCOMYCIN EXPOSURE; INTERMITTENT; PHARMACODYNAMICS; GUIDELINES; MEROPENEM; PIPERACILLIN;
D O I
10.1080/14787210.2020.1764845
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Critically ill patients with acute kidney injury often require renal replacement therapy and antibiotic therapy. Mortality rates are high in these patients, possibly due to ineffective dosing due to altered pharmacokinetic profiles and drug removal by renal replacement therapy. Areas covered: The main types of renal replacement therapies are intermittent hemodialysis, prolonged intermittent renal replacement therapy and continuous renal replacement therapy. Each of these renal replacement therapies may have drastic, yet different, effects on antibiotic serum concentration profiles. Moreover, three antibiotic administration strategies are often used: (1) standard infusion; (2) extended infusion; and (3) continuous infusion. A literature review was conducted on Medline in December 2019 to identify pertinent research. Expert opinion: Renal replacement therapies used in the treatment of acute kidney injury in critically ill patients usually complicates antibiotic use. Although antibiotic toxicity can be seen, most studies find that these patients do not receive sufficient antibiotic doses to achieve desired pharmacodynamic targets. Clinicians should dose antibiotics to match renal replacement therapy drug clearance characteristics to antibiotic pharmacodynamic profiles.
引用
收藏
页码:887 / 895
页数:9
相关论文
共 52 条
[21]   A Monte Carlo Simulation Approach for Beta-Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy [J].
Jang, Soo Min ;
Gharibian, Katherine N. ;
Lewis, Susan J. ;
Fissell, William H. ;
Tolwani, Ashita J. ;
Mueller, Bruce A. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (10) :1254-1265
[22]   Impact of Vancomycin Exposure on Outcomes in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia: Support for Consensus Guidelines Suggested Targets [J].
Kullar, Ravina ;
Davis, Susan L. ;
Levine, Donald P. ;
Rybak, Michael J. .
CLINICAL INFECTIOUS DISEASES, 2011, 52 (08) :975-981
[23]  
Langenberg C, 2008, CRIT CARE, V12, DOI [10.1186/cc6823, 10.1186/cc6863, 10.1186/cc6268]
[24]  
Lewis SJ., 2016, RENAL REPLACE THER, V2, P1, DOI DOI 10.1186/S41100-016-0055-X
[25]   Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation [J].
Lewis, Susan J. ;
Mueller, Bruce A. .
SAGE OPEN MEDICINE, 2018, 6
[26]   Antibiotic Dosing in Patients With Acute Kidney Injury: "Enough But Not Too Much" [J].
Lewis, Susan J. ;
Mueller, Bruce A. .
JOURNAL OF INTENSIVE CARE MEDICINE, 2016, 31 (03) :164-176
[27]   Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy [J].
Lewis, Susan J. ;
Kays, Michael B. ;
Mueller, Bruce A. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (10) :1277-1287
[28]   Antibiotic Dosing in Critically Ill Patients Receiving CRRT: Underdosing is Overprevalent [J].
Lewis, Susan J. ;
Mueller, Bruce A. .
SEMINARS IN DIALYSIS, 2014, 27 (05) :441-445
[29]   Vancomycin Exposure in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: How Much Is Enough? [J].
Lodise, Thomas P. ;
Drusano, George L. ;
Zasowski, Evan ;
Dihmess, Amanda ;
Lazariu, Victoria ;
Cosler, Leon ;
McNutt, Louise-Anne .
CLINICAL INFECTIOUS DISEASES, 2014, 59 (05) :666-675
[30]   Gentamicin pharmacokinetics during slow daily home hemodialysis [J].
Manley, HJ ;
Bailie, GR ;
McClaran, ML ;
Bender, WL .
KIDNEY INTERNATIONAL, 2003, 63 (03) :1072-1078